



Published in final edited form as:

Surg Obes Relat Dis. 2023 August ; 19(8): 799–807. doi:10.1016/j.soard.2022.12.038.

Venous thromboembolism (VTE) prophylaxis after bariatric surgery: a national survey of MBSAQIP director practices

Spyridon Giannopoulos, M.D.^a, Seyed Mohammad Kalantar Motamedi, M.D., M.P.H.^a, Dimitrios I. Athanasiadis, M.D.^a, Benjamin Clapp, M.D.^b, Victoria Lyo, M.D.^c, Omar Ghanem, M.D.^d, Michael Edwards, M.D.^e, Nancy Puzifferri, M.D.^f, Dimitrios Stefanidis, M.D., Ph.D.^{a,*}, ASMBS Research Committee

^aDepartment of Surgery, Indiana University School of Medicine, Indianapolis, Indiana

^bPaul Foster School of Medicine, Texas Tech HSC, El Paso, Texas

^cDepartment of Surgery, University of California Davis, Sacramento, California

^dDepartment of Surgery, Mayo Clinic, Rochester, Minnesota

^eDepartment of Surgery, Mayo Clinic, Jacksonville, Florida

^fDepartment of Surgery, Oregon Health & Science University, Portland, Oregon

Abstract

Background: Venous thromboembolism (VTE) is the most common cause of death following metabolic/bariatric surgery (MBS), with most events occurring after discharge. The available evidence on ideal prophylaxis type, dosage, and duration after discharge is limited.

Objectives: Assess metabolic/bariatric surgeon VTE prophylaxis practices and define existing variability.

Setting: Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)-accredited centers.

Methods: The members of the ASMBS Research Committee developed and administered a web-based survey to MBSAQIP medical directors and ASMBS members to examine the differences in clinical practice regarding the administration of VTE prophylaxis after MBS.

Results: Overall, 264 metabolic/bariatric surgeons (136 medical directors and 128 ASMBS members) participated in the survey. Both mechanical and chemical VTE prophylaxis was used by 97.1% of the participants, knee-high compression devices by 84.7%, enoxaparin (32.4% 40 mg every 24 hours, 22.7% 40 mg every 12 hours, 24.4% adjusted the dose based on body mass

*Correspondence: Dimitrios Stefanidis, M.D., Ph.D., Department of Surgery, Indiana University School of Medicine, 545 Barnhill Dr, Indianapolis, Indiana 46202. dimstefa@iu.edu (D. Stefanidis).

Authors' contributions

The authors confirm contribution to the paper as follows: Study conception and design: Stefanidis D, Athanasiadis D., Giannopoulos S, Clapp B., Lyo V., Ghanem O., Puzifferri N, Edwards M; Data collection: Giannopoulos S, Athanasiadis D; Analysis and interpretation of results: Giannopoulos S, Stefanidis D; Kalantar Motamedi SM; Draft preparation: Giannopoulos S; Stefanidis D; Kalantar Motamedi SM; Critical content revision: Stefanidis D., Clapp B., Lyo V., Ghanem O., Puzifferri N;

Supplementary data

Supplementary material associated with this article can be found, in the online version, at <https://doi.org/10.1016/j.soard.2022.12.038>.

index) by 56.5%, and heparin (46.1% 5000 units every 8 hours, 22.6% 5000 units every 12 hours, 20.9% 5000 units once preoperatively) by 38.1%. Most surgeons (81.6%) administered the first dose preoperatively, while the first postoperative dose was given on the evening of surgery by 44% or the next morning by 42.2%. Extended VTE prophylaxis was prescribed for 2 weeks by 38.7% and 4 weeks by 28.9%.

Conclusions: VTE prophylaxis practices vary widely among metabolic/bariatric surgeons. Variability may be related to limited available comparative evidence. Large prospective clinical trials are needed to define optimal practices for VTE risk stratification and prophylaxis in bariatric surgery patients.

Keywords

Bariatric surgery; Venous thromboembolism (VTE) prophylaxis; Mechanical prophylaxis; Chemoprophylaxis; Survey

Metabolic/bariatric surgery (MBS) offers the most effective treatment for obesity and related medical problems. It improves the overall life expectancy more than nonsurgical weight control methods and is considered very safe with less than .1% overall mortality [1–5]. However, venous thromboembolism (VTE) events, including pulmonary embolism (PE) and deep vein thrombosis (DVT), occur in .1%–2% and 1%–3% of MBS [6,7]. Although the lifetime risk of VTE and mortality decreases with MBS, it remains one of the most common causes of mortality postoperatively [8–11]. VTE may occur during hospitalization, but 73%–83% of the events happen after discharge [11–14]. Thus, in-hospital and postdischarge prophylaxis is of utmost importance.

The American Society of Metabolic and Bariatric Surgeons (ASMBS) conducted 2 surveys previously, 1 in 1998 [15] and then 10 years later in 2007 [6] in order to evaluate the practices of metabolic/bariatric surgeons regarding prophylaxis of VTE. During that time, there have been changes in practice patterns; namely, the use of low molecular weight heparin (LMWH) increased from 13% in 1998 to 58.4% in 2007. Since then, many studies have added to the body of evidence, and the ASMBS also issued an updated position statement in 2022 [16]. In addition many VTE risk assessment models (RAM) have been developed to help physicians optimize their targets for prophylaxis [10,11,17,18]. New guidelines have been recently issued by surgical and medical societies based on available evidence to recommend standard prophylaxis protocols [19–21]. Due to the rare incidence of VTE, high-quality comparative evidence of prophylaxis choices is scarce [19,22]. Such uncertainty further affects the dosage, frequency, time of initiation, and total duration of administration of chemoprophylactic agents. Further, current VTE RAMs do not take postoperative bleeding risk into account [11,17,23].

In this context, the standardization of VTE prophylaxis practices may be difficult, as the current existing evidence is based on low-level data, requiring metabolic/bariatric surgeons to make decisions based on their clinical judgment. Such conditions can, however, result in inconsistencies in patient care. Our objective in this study was to evaluate current patterns of practice in VTE prophylaxis among metabolic/bariatric surgeons and define existing variability that might inform new trials for improving standards of care in MBS.

Methods

The Research Committee of the ASMBS [24] created a questionnaire to examine the differences in clinical practice regarding the administration of VTE prophylaxis perioperatively and after MBS. Prior to distributing the survey, an institutional review board exemption was obtained. This survey was part of an effort of the ASMBS Research Committee to establish a research collaboration among Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP)-accredited centers. The interest of MBSAQIP-accredited center medical directors was initially solicited via email contact. The survey was distributed twice to this group of 215 medical directors in November 2021 via a web-based anonymous link, allowing for a minimum of 1-week interval until the second dissemination. The invitation provided a brief background of the study's purpose and the topic to be assessed. After collecting the responses of the medical directors, the participation was extended to the entire ASMBS membership. As such, the survey was posted in the ASMBS newsletter in December 2021 and January 2022.

The survey was created using an online survey platform (Qualtrics, Provo, Utah, USA), where the answers were collected and stored. The participation was voluntary and confidential as all responses were deidentified and only cumulative results or anonymous individual responses were presented. The survey was conducted in English and was closed for analysis on February 4th, 2022.

The questionnaire included 28 multiple-choice and open-guided questions (Appendix 1). It was developed by a working group of the ASMBS Research Committee using an iterative process [25,26] and was piloted with Research Committee members before being finalized based on provided feedback. Questions regarding demographic information (e.g., surgeon's ethnicity and gender), occupational characteristics (e.g., years in practice after fellowship, practice type of primary location, and annual metabolic/bariatric volume of the program), and differences in VTE prophylaxis, such as type of medication, dose, frequency of administration, duration post-discharge, initiation after surgery, and complications, were presented to participants. A separate answer, mentioned as "Other," was included in each question, and a box to specify their choice was provided to ensure the collection of all possible answers. In this context, this survey aimed only to detect and analyze differences in clinical practices among metabolic/bariatric surgeons and not to identify the most beneficial VTE prophylaxis.

Descriptive statistics were used to analyze the survey results, and qualitative data from the open-text box questions were analyzed accordingly. Additionally, a separate analysis of the responses in the medical directors' group versus ASMBS members was conducted to investigate variations in surgeons' practices based on their position. Binary variables were presented as absolute or relative frequencies. Chi-square test or Fisher's exact test, when applicable, were used to determine significant variables. For all tests, $P < .05$ was considered significant. All statistical analyses were performed with STATA 16.0 software (STATA Corporation, College Station, TX, USA).

Results

Two hundred sixty-four surgeons participated in the survey, with 136 being medical directors and 128 surgeons from the ASMBS membership, with the vast majority of them completing the survey (85%). The calculated response rate for the 2 groups was 63% for the directors and 4% for the broader membership. The baseline characteristics of each group are presented in Table 1. The groups were similar in terms of gender composition, ethnicity, and practice type of the primary location. However, surgeons in the medical director group had more years in practice after fellowship and were employed at higher volume programs.

Surgeons' responses to the questions related to clinical practice differences during and after hospitalization are presented in Table 2. In both groups, almost all surgeons (97.1%) used chemoprophylaxis (CP) combined with mechanical prophylaxis (MP). Of those offering MP, 84.7% selected knee-length sequential compression devices (SCD), 5.2% SCDs combined with thromboembolus deterrent (TED) hose, and 4.8% thigh-length SCDs. The type of MP was similar across the groups, with only the combination of TED hose and SCDs being more frequently used by ASMBS participants than the directors (Table 3). Of the surgeons administering CP before and after MBS, enoxaparin (56.5%) and heparin (38.1%) were the most preferred anticoagulants regardless of the group surgeons belonged to. In most cases, perioperative CP administration was initiated just before the operation in the preoperative area (81.6%), and the patient resumed anticoagulation the evening of surgery (44%) or the next morning (42.2%) (Table 2). The practices regarding the dose ($P = .07$ for heparin; $P = .153$ for enoxaparin) and frequency ($P = .501$ for heparin; $P = .09$ for enoxaparin) of VTE CP did not differ significantly between the groups (Table 4). The most common dosage options for enoxaparin were 40 mg every 24 hours (32.4%), 40 mg every 12 hours (22.7%), and adjusted dose based on body mass index (BMI) (24.4%), while for heparin it was 5000 units every 8 hours (46.1%) and 5000 units every 12 hours (22.6%).

After discharge, 73.8% of both medical directors and AMSBS members provided VTE CP only to select patients, and the most common duration was 2 weeks followed by 4 weeks, while 13.8% did not administer anticoagulants (Table 2). Most respondents who selected "Other" mentioned a period of 2–4 weeks CP based on the risk for VTE. Enoxaparin was the most frequently prescribed anticoagulant for extended VTE prophylaxis, reaching 80.1%. Apixaban and Rivaroxaban were selected by 10.5% and 5.5%, respectively.

Modification of the VTE prophylaxis protocol when there is a concern about bleeding was selected by 66.2% of the participants (Table 5). They indicated that the most common reason for this was excessive intraoperative bleeding or concerning operative findings (36.1%), followed by increased risk of bleeding (12.7%), significant hemoglobin/hematocrit drop postoperatively (8.9%), and active postoperative bleeding (8.2%). Moreover, 19.4% of surgeons had encountered PE in patients under CP. Postoperative complications related to bleeding were the most frequently reported factor that kept surgeons from using extended CP (Table 5). Surgeons reported a wide range of criteria on how they decide to administer extended prophylaxis (Table 6). However, family history of PE/DVT (17.2%), presence of hypercoagulable state (15.8%), immobility/paraplegia (12.2%), and increased BMI were amongst the most popular. Of these criteria, history of PE/DVT and hypercoagulable state

were selected more frequently by the ASMBS membership participants than the medical directors.

Discussion

The present study examined the current clinical practice variability among MBSAQIP program directors regarding VTE prophylaxis after MBS. Our study showed that almost all metabolic/bariatric surgeons who responded to the survey considered VTE prophylaxis as a critical part of their practice. Specifically, they reported using both mechanical and chemical prophylaxis to prevent VTE in their patients during hospitalization. However, the clinical patterns regarding the type of medication, dosage, time of initiation, frequency, and duration of administration varied substantially among surgeons. This inconsistency was observed in both the medical director and the ASMBS membership groups.

Based on the results of the present study, the ASMBS Research Committee has established a multicenter collaboration among MBSAQIP-accredited centers aspiring to identify the optimal pattern of VTE prophylaxis (e.g., dose, frequency, post-discharge duration of administration) and maximize the benefits for patients following bariatric surgery. This collaboration aims to create a prospective multisite database that will include all MBSAQIP variables and carefully selected VTE prophylaxis data. The first goal will be to investigate the timing of VTE prophylaxis. Therefore, the primary outcomes will include the effect of preoperative, in-hospital, and postdischarge VTE prophylaxis on bariatric surgery outcomes at 90 days postoperatively. The results of this prospective study are expected to provide valuable insights regarding the future standard of care for VTE chemoprophylaxis after bariatric surgery. Although several surveys exploring VTE prophylaxis practices in MBS have been published over the past few years [6,27–29], this is the first comprehensive study to capture all critical clinical pattern questions without focusing only on one aspect (e.g., only type of medication or time of administration, etc.). Since the last survey of ASMBS members in 2007 [6], several studies, risk assessment tools, and guidelines have been released or revised to improve standards of care for the prevention of VTE, indicating the need for an update of the current VTE prophylaxis patterns of ASMBS members.

The previous ASMBS survey reported that 94% and 98% of surveyed surgeons routinely administered CP and MP [6]. This aligns with the results of our study, where almost all metabolic/bariatric surgeons (97.1%) utilized both mechanical and chemical prophylaxis at the time of surgery. This VTE prevention practice is consistent with current guidelines and recommendations [19,20,22]. In another survey of 385 members of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) in 2012, 92% of surgeons applied SCDs on high-risk patients postoperatively, with 97% of them also receiving CP [27]. As such, it seems that the need for both MP and CP in the perioperative setting is well-established and accepted by metabolic/bariatric surgeons [17]. Moreover, all bariatric patients are considered at least moderate risk for VTE, and thus, in the absence of high risk for bleeding, they would benefit from both CP and MP [17,18,30].

When it comes to the specific type of MP, the use of SCD has shifted from 60% in 2007 to 90% today [6]. This finding aligns with the reports of Pryor et al., where 92%

of the surgeons used SCDs postoperatively [27], and the recommendations of the Clinical Issues Committee of ASMBS [31]. Moreover, the recent American Society of Hematology (ASH) guidelines by the ASH recommended the use of SCDs over graduated compression stockings in hospitalized surgical patients [19]. In contrast, a French multicenter survey reported that the most common type of MP in bariatric patients was the combination of SCD and compression stocking (39%), followed by compression stocking alone (32%), and SCD alone (26%) [28].

Regarding the choice of postoperative CP, LMWH was the most preferred (57%) type of anticoagulation in our study. This percentage did not drastically differ from the ones reported by ASMBS members in 2007 (60%) and SAGES members in 2012 (50%) [6,27]. Along those lines, Moulin et al. described that 90% of the respondents in their survey were using LMWH routinely in the postoperative setting [28]. This finding is not surprising, as it is consistent with the updated ASMBS 2022 VTE prophylaxis guidelines [16], which were based on national and international data. In accordance with several studies showing the LMWH effectiveness in this patient population [32–35], ASMBS recommended in favor of LMWH. Similarly, the European Society of Anesthesiology VTE Guideline Task Force supported LMWH over unfractionated heparin [21].

The most common in-hospital enoxaparin dosage reported in the current survey was 40 mg every 24 hrs (32.4%) and 40 mg every 12 hrs (22.7%), while the corresponding percentages in the previous ASMBS report were 21.1% and 45.4%, respectively [6]. At the same time, 83% of French centers prescribing enoxaparin used 80 mg daily [28]. Protocols using weight-adjusted enoxaparin dosing have been described in the literature for morbidly obese patients [36], with some studies suggesting dose corrections based on the antifactor Xa levels [37]. When comparing the current with previous surveys, we observed similar differences in heparin doses. We found 5000 IU every 8 hrs (46.1%) to be the most frequently selected dosage compared to 62.1% in other studies [6]. Having said that, none of the doses for either type of CP stood out, confirming the substantial variability and lack of standardization of doses and administration intervals.

Most of our respondents favored initiation of CP preoperatively (82%). This number was higher among SAGES respondents (92%), while conversely, in the French national survey [28], only 15% of centers were administering preoperative CP. Evidence for the best initiation time of prophylaxis is not yet conclusive due to the paucity of high-quality evidence in MBS; therefore, the ASMBS did not have any specific recommendation in 2013 [30]. However, the guidelines are all based on low to moderate level of evidence [21,22,30].

We also found that the surgeons' practices are largely diverse regarding the administration and duration of postdischarge extended CP. In our study, the percentage of surgeons considering extended CP was 74% versus the slightly lower 60% reported in older studies, but still the duration ranged from 1 to 4 weeks [6]. In contrast, in the SAGES survey, 44% of the participants prescribed CP post-discharge, mainly for 2–4 weeks. In this context, several studies have attempted to find a balance between overtreatment and the optimal level of VTE prevention. Specifically, Aminian et al [11]. suggested 3 levels of VTE risk (<.4%, >.4%, and >1%) to help surgeons decide on extended CP. According to these recommendations,

patients in the first group should not receive extended CP, while those in the second and third should be covered with CP for 2- and 4-weeks postdischarge, respectively.

In our survey, we observed that surgeons considered only a fraction of the risk factors as criteria for a decision on extended CP. Very few (5.4%) participants in our survey considered anti-Xa level monitoring or duplex sonography for decision-making. Furthermore, only 11.3% of respondents use any type of RAM, which is inconsistent with the ASMBS recommendations and the guidelines on extended CP [11,17,19,20,22,30]. The lack of awareness about the most recent evidence or recommendations may be the reason for the nonapplication of these measures. In addition, the literature suggests that it may take up to 17 years for only 14% of published evidence to be implemented into clinical practice [38,39]. As such, we expect these VTE prophylaxis guidelines to become an integral part of postoperative bariatric patient care in the future. Finally, filling out RAM forms can be time-consuming and not feasible for all. Some RAMs have developed and validated patient-friendly versions so that patients can reliably report VTE risk scores. This approach may remove the burden from practices and improve the utilization rate [40,41].

This study has inherent limitations such as sampling, nonresponse, recall, and social desirability bias. We tried to minimize these issues first by designing a concise and clear questionnaire while balancing the survey's convenience and comprehensiveness. We excluded personal and identifiable questions which might trigger social desirability bias. Secondly, we choose a secure and online form for easier access and anonymous data collection. Thirdly, the survey was sent out multiple times at reasonable intervals (a minimum of 1 week between each distribution), primarily to the medical directors and then to the entire ASMBS membership. As expected, directly inviting medical directors via email to participate in our survey resulted in a high response rate (60%) in this group, especially considering the consistently lower rates in web-based surveys compared to other survey modes [42]. However, the different strategy for participant enrollment in the ASMBS membership survey by posting the link in the ASMBS newsletter resulted in a significantly lower response rate [43]. This is in line with current literature, where response rates as low as 2% have been reported [44]. As a result, the responses of the ASMBS membership may not be generalizable to the entire society.

The necessity for mechanical and/or chemical VTE prophylaxis in the inpatient and postdischarge setting after the metabolic/bariatric procedure was recognized by participating surgeons. However, practices related to the type of CP agents, dosing, frequency, timing, and duration of extended administration varied widely among respondents, reflecting several gaps in the literature regarding best practices for VTE risk stratification and prophylaxis in MBS patients. In view of the above, there is an absolute need for well-designed multicentric studies to optimize VTE prophylaxis following MBS.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank Mrs Karen Loerzel, support staff of the ASMBS research committee for her help in administering the survey to our participants.

Disclosures

Dr. Dimitrios Stefanidis has received institutional research support from Becton Dickinson and Intuitive which are not related to this study. All the authors have no commercial associations that might be a conflict of interest in relation to this article.

References

- [1]. Carlsson LMS, Sjöholm K, Jacobson P, et al. Life expectancy after bariatric surgery in the Swedish obese subjects study. *N Engl J Med* 2020;383(16):1535–43. [PubMed: 33053284]
- [2]. Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. *J Intern Med* 2013;273(3):219–34. [PubMed: 23163728]
- [3]. Cardoso L, Rodrigues D, Gomes L, Carrilho F. Short- and long-term mortality after bariatric surgery: a systematic review and meta-analysis. *Diabetes Obes Metab* 2017;19(9):1223–32. [PubMed: 28244626]
- [4]. Chang S-H, Stoll CRT, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. *JAMA Surg* 2014;149(3):275–87. [PubMed: 24352617]
- [5]. Aminian A, Brethauer SA, Kirwan JP, Kashyap SR, Burguera B, Schauer PR. How safe is metabolic/diabetes surgery? *Diabetes Obes Metab* 2015;17(2):198–201. [PubMed: 25352176]
- [6]. Barba CA, Harrington C, Loewen M. Status of venous thromboembolism prophylaxis among bariatric surgeons: have we changed our practice during the past decade? *Surg Obes Relat Dis* 2009;5(3):352–6. [PubMed: 19342305]
- [7]. Wesley Vosburg R, Druar NM, Kim JJ. Factors associated with increased risk for pulmonary embolism after metabolic and bariatric surgery: analysis of nearly one million patients. *Obes Surg* 2022;32(7):2433–7. [PubMed: 35568750]
- [8]. Morino M, Toppino M, Forestieri P, Angrisani L, Allaix ME, Scopinaro N. Mortality after bariatric surgery: analysis of 13,871 morbidly obese patients from a national registry. *Ann Surg* 2007;246(6):1002–9. [PubMed: 18043102]
- [9]. Smith MD, Patterson E, Wahed AS, et al. Thirty-day mortality after bariatric surgery: independently adjudicated causes of death in the longitudinal assessment of bariatric surgery. *Obes Surg* 2011;21(11):1687–92. [PubMed: 21866378]
- [10]. Dang JT, Switzer N, Delisle M, et al. Predicting venous thromboembolism following laparoscopic bariatric surgery: development of the BariClot tool using the MBSAQIP database. *Surg Endosc* 2019;33(3):821–31. [PubMed: 30003351]
- [11]. Aminian A, Andalib A, Khorgami Z, et al. Who should get extended thromboprophylaxis after bariatric surgery?: a risk assessment tool to guide indications for post-discharge pharmacoprophylaxis. *Ann Surg* 2017;265(1):143–50. [PubMed: 28009739]
- [12]. Steele KE, Schweitzer MA, Prokopowicz G, et al. The long-term risk of venous thromboembolism following bariatric surgery. *Obes Surg* 2011;21(9):1371–6. [PubMed: 21625911]
- [13]. Helm MC, Simon K, Higgins R, Kindel TL, Gould JC. Perioperative complications increase the risk of venous thromboembolism following bariatric surgery. *Am J Surg* 2017;214(6):1135–40. [PubMed: 28958647]
- [14]. Winegar DA, Sherif B, Pate V, DeMaria EJ. Venous thromboembolism after bariatric surgery performed by bariatric surgery center of excellence participants: analysis of the bariatric outcomes longitudinal database. *Surg Obes Relat Dis* 2011;7(2):181–8. [PubMed: 21421182]
- [15]. Wu EC, Barba CA. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. *Obes Surg* 2000;10(1):7–13; discussion 4. [PubMed: 10715636]

- [16]. Aminian A, Vosburg RW, Altieri MS, Hinojosa MW, Khorgami Z. The American Society for Metabolic and Bariatric Surgery (ASMBS) updated position statement on perioperative venous thromboembolism prophylaxis in bariatric surgery. *Surg Obes Relat Dis* 2022;18(2):165–74. [PubMed: 34896011]
- [17]. Finks JF, English WJ, Carlin AM, et al. Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. *Ann Surg* 2012;255(6):1100–4. [PubMed: 22566018]
- [18]. Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. *Am J Surg* 2010;199(1):S3–10. [PubMed: 20103082]
- [19]. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. *Blood Adv* 2019;3(23):3898–944. [PubMed: 31794602]
- [20]. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists - Executive Summary. *Endocr Pract* 2019;25(12):1346–59. [PubMed: 31682518]
- [21]. Venclauskas L, Maleckas A, Arcelus JI. European guidelines on perioperative venous thromboembolism prophylaxis: surgery in the obese patient. *Eur J Anaesthesiol* 2018;35(2):147–53. [PubMed: 29112546]
- [22]. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2 Suppl):e227S–77S. [PubMed: 22315263]
- [23]. Pannucci CJ, Laird S, Dimick JB, Campbell DA, Henke PK. A validated risk model to predict 90-day VTE events in postsurgical patients. *Chest* 2014;145(3):567–73. [PubMed: 24091567]
- [24]. American Society of Metabolic and Bariatric Surgery (ASMBS) Research Committee. 2022 [cited 2022 Jun 6]; Available from, <https://asmbs.org/committees/research-committee>.
- [25]. Burns KE, Duffett M, Kho ME, et al. A guide for the design and conduct of self-administered surveys of clinicians. *CMAJ* 2008;179(3):245–52. [PubMed: 18663204]
- [26]. Hing CB, Smith TO, Hooper L, Song F, Donell ST. A review of how to conduct a surgical survey using a questionnaire. *Knee* 2011;18(4):209–13. [PubMed: 21115354]
- [27]. Pryor HI 2nd, Singleton A, Lin E, Lin P, Vaziri K. Practice patterns in high-risk bariatric venous thromboembolism prophylaxis. *Surg Endosc* 2013;27(3):843–8. [PubMed: 23052502]
- [28]. Moulin PA, Dutour A, Ancel P, et al. Perioperative thromboprophylaxis in severely obese patients undergoing bariatric surgery: insights from a French national survey. *Surg Obes Relat Dis* 2017;13(2):320–6. [PubMed: 27720420]
- [29]. Bhattacharya S, Kumar SS, Swamy PDK, Palanivelu C, Raj PP. Deep vein thrombosis prophylaxis: are we overdoing? An Asian survey on trends in bariatric surgery with a systematic review of literature. *J Minim Access Surg* 2018;14(4):285–90. [PubMed: 29226883]
- [30]. ASMBS updated position statement on prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients. *Surg Obes Relat Dis* 2013;9(4):493–7. [PubMed: 23769113]
- [31]. Prophylactic measures to reduce the risk of venous thromboembolism in bariatric surgery patients. *Surg Obes Relat Dis* 2007;3(5):494–5. [PubMed: 17903767]
- [32]. Birkmeyer NJ, Finks JF, Carlin AM, et al. Comparative effectiveness of unfractionated and low-molecular-weight heparin for prevention of venous thromboembolism following bariatric surgery. *Arch Surg* 2012;147(11):994–8. [PubMed: 23165612]
- [33]. Hamadi R, Marlow CF, Nassereddine S, Taher A, Finianos A. Bariatric venous thromboembolism prophylaxis: an update on the literature. *Expert Rev Hematol* 2019;12(9):763–71. [PubMed: 31219356]

- [34]. Borkgren-Okonek MJ, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. *Surg Obes Relat Dis* 2008;4(5):625–31. [PubMed: 18261965]
- [35]. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. *Obes Surg* 2005;15(10):1368–74. [PubMed: 16354513]
- [36]. Sebastian R, Ghanem O, DiRoma F, Milner SM, Price LA. Pulmonary embolism in burns, is there an evidence based prophylactic recommendation? Case report and review of literature. *Burns* 2015;41(2):e4–7. [PubMed: 25115669]
- [37]. Lin H, Faraklas I, Cochran A, Saffle J. Enoxaparin and antifactor Xa levels in acute burn patients. *J Burn Care Res* 2011;32(1):1–5. [PubMed: 21124231]
- [38]. Westfall JM, Mold J, Fagnan L. Practice-based research—“Blue Highways” on the NIH roadmap. *JAMA* 2007;297(4):403–6. [PubMed: 17244837]
- [39]. Balas EA, Boren SA. Managing clinical knowledge for Health care improvement. *Yearb Med Inform* 2000;(1):65–70. [PubMed: 27699347]
- [40]. Fuentes HE, Paz LH, Al-Ogaili A, et al. Validation of a patient-completed caprini risk score for venous thromboembolism risk assessment. *TH Open* 2017;1(2):e106–12. [PubMed: 31249916]
- [41]. Paz Rios LH, Fuentes HE, Oramas DM, et al. Validation of a patient-completed caprini risk assessment tool for Spanish, Arabic, and polish speakers. *Clin Appl Thromb Hemost* 2018;24(3):502–12. [PubMed: 29258392]
- [42]. Daikeler J, Bošnjak M, Lozar Manfreda K. Web versus other survey modes: an updated and extended meta-analysis comparing response rates. *J Surv Stat Methodol* 2019;8(3):513–39.
- [43]. Banning LBD, Meyer VM, Keupers J, Lange JFM, Pol RA, Benjamens S. Surveys in surgical education: a systematic review and reporting guideline. *Eur Surg Res* 2021;62(2):61–7. [PubMed: 33951638]
- [44]. Petchenik J, Watermolen DJ. A cautionary note on using the internet to survey recent Hunter education graduates. *Hum Dimensions Wildl* 2011;16(3):216–8.

Table 1

Baseline characteristics of participants by group

| Questions | Medical directors | Membership | Total | P value |
|--|-------------------|------------|-------------|---------|
| What is the practice type of your primary location? | | | | |
| Academic | 34 (30.6%) | 37 (30.1%) | 71 (30.3%) | .058 |
| Hospital-employed | 52 (48.9%) | 40 (32.5%) | 92 (39.3%) | |
| Multi-specialty clinic-employed | 1 (.9%) | 1 (.8%) | 2 (.9%) | |
| Private practice | 24 (21.6%) | 45 (36.6%) | 69 (29.5%) | |
| Approximately what is your program's bariatric volume? | | | | |
| 0-49 | 2 (1.8%) | 9 (7.3%) | 11 (4.7%) | .007* |
| 50-99 | 18 (16.1%) | 10 (8.1%) | 28 (11.9%) | |
| 100-200 | 32 (28.6%) | 21 (17.1%) | 53 (22.6%) | |
| >200 | 60 (53.6%) | 83 (67.5%) | 143 (60.9%) | |
| What is your sex? | | | | |
| Female | 27 (25.2%) | 25 (20.3%) | 52 (22.6%) | .472 |
| Male | 76 (71%) | 96 (78.1%) | 172 (74.8%) | |
| Other | 1 (.9%) | 0 (0%) | 1 (.4%) | |
| Prefer not to say | 3 (2.8%) | 2 (1.6%) | 5 (2.2%) | |
| How many years in practice following fellowship? | | | | |
| <5 | 14 (13.3%) | 39 (31.7%) | 53 (23.3%) | .010* |
| 5-10 | 20 (19.1%) | 21 (17.1%) | 41 (18%) | |
| 10-15 | 17 (16.2%) | 18 (14.6%) | 35 (15.4%) | |
| >15 | 54 (51.4%) | 45 (36.6%) | 99 (43.4%) | |
| What is your ethnicity? | | | | |
| White | 76 (73.8%) | 86 (72.9%) | 162 (73.3%) | .786 |
| Black/ African American | 5 (4.9%) | 4 (3.4%) | 9 (4.1%) | |
| Asian | 15 (14.6%) | 16 (13.6%) | 31 (14%) | |
| Other | 7 (6.8%) | 12 (10.2%) | 19 (8.6%) | |

Data are expressed as n (%).

*The difference is significant at the .05 level.

Table 2**Type and duration of VTE prophylaxis during and after hospitalization**

| Questions | Medical directors | Membership | Total | P value |
|--|-------------------|-------------|-------------|---------|
| What type of VTE prophylaxis do you use for your bariatric patients? | | | | |
| Chemoprophylaxis and mechanical | 114 (98.3%) | 120 (96%) | 234 (97.1%) | .105 |
| Chemoprophylaxis only | 0 (0%) | 4 (3.2%) | 4 (1.7%) | |
| Mechanical prophylaxis only | 1 (.9%) | 0 (0%) | 1 (.4%) | |
| Other (please define) | 1 (.9%) | 1 (.8%) | 2 (.8%) | |
| When do you administer the first dose of the chemoprophylaxis? | | | | |
| During the operation (after incision) | 1 (.9%) | 1 (.8%) | 2 (.9%) | .983 |
| During the operation (before incision) | 7 (6.4%) | 8 (6.5%) | 15 (6.4%) | |
| Just before the operation (Preoparea) | 89 (80.9%) | 101 (82.1%) | 190 (81.6%) | |
| Only after the operation | 13 (11.8%) | 13 (10.6%) | 26 (11.2%) | |
| When do you administer the first postoperative dose of chemoprophylaxis? | | | | |
| After "X" hours | 18 (16.5%) | 14 (11.4%) | 32 (13.8%) | .476 |
| The evening of surgery | 48 (44%) | 54 (43.9%) | 102 (44%) | |
| The next morning | 43 (39.5%) | 55 (44.7%) | 98 (42.2%) | |
| Do you use extended chemoprophylaxis on discharge? | | | | |
| No | 17 (14.9%) | 16 (12.7%) | 33 (13.7%) | .425 |
| Yes, on all patients | 11 (9.7%) | 19 (15.1%) | 30 (12.5%) | |
| Yes, on selective patients | 86 (75.4%) | 91 (72.2%) | 177 (73.8%) | |
| For how long? | | | | |
| 1 wk | 3 (3.4%) | 10 (9.4%) | 13 (6.7%) | .462 |
| 2 wk | 38 (43.2%) | 37 (34.9%) | 75 (38.7%) | |
| 3 wk | 6 (6.8%) | 7 (6.6%) | 13 (6.7%) | |
| 4 wk | 24 (27.3%) | 32 (30.2%) | 56 (28.9%) | |
| Other | 17 (19.3%) | 20 (18.9%) | 37 (19.1%) | |

VTE = venous thromboembolism.

Data are expressed as n (%).

P value is calculated using Chi-square or Fisher's exact test when appropriate.

Table 3

Types of mechanical and chemical prophylaxis during hospitalization

| Questions | Medical directors | Membership | Total | P value |
|---|-------------------|-------------|-------------|---------|
| What type of mechanical VTE prophylaxis do you use? (Preop and during hospitalization) [†] | | | | |
| (SCD) - knee length | 106 (86.9%) | 104 (82.5%) | 210 (84.7%) | .111 |
| (SCD) - thigh length | 6 (4.9%) | 6 (4.8%) | 12 (4.8%) | .927 |
| TED hose | 3 (2.5%) | 1 (.8%) | 4 (1.6%) | .359 |
| TED hose and SCDs | 2 (1.6%) | 11 (8.7%) | 13 (5.2%) | .013* |
| Ambulation only | 2 (1.6%) | 2 (1.6%) | 4 (1.6%) | 1.000 |
| Other | 3 (2.5%) | 2 (1.6%) | 5 (2%) | .677 |
| What type of chemical VTE prophylaxis do you use? (Preop and during hospitalization) [†] | | | | |
| Heparin | 56 (39.2%) | 64 (37.2%) | 120 (38.1%) | .805 |
| Enoxaparin | 81 (56.6%) | 97 (56.4%) | 178 (56.5%) | .293 |
| Apixaban | 2 (1.4%) | 2 (1.2%) | 4 (1.3%) | 1.000 |
| Rivaroxaban | 0 (0%) | 2 (1.2%) | 2 (.6%) | .499 |
| Fondaparinux | 2 (1.4%) | 2 (1.2%) | 4 (1.3%) | 1.000 |
| Other | 2 (1.4%) | 5 (2.9%) | 7 (2.2%) | .310 |

VTE = venous thromboembolism; SCD = sequential compression devices; TED = thromboembolus deterrent.

Data are expressed as n (%).

P value is calculated using Chi-square or Fisher's exact test when appropriate.

* The difference is significant at the .05 level.

[†] Multiple response questions.

Table 4

Dose and frequency of VTE prophylaxis during hospitalization

| Questions | Medical Directors | Membership | Total | P value |
|--|-------------------|-------------|-------------|---------|
| What is the dose you use (Heparin)? | | | | |
| 5000 units | 40 (72.7%) | 55 (85.9%) | 95 (79.8%) | .070 |
| 7500 units | 8 (15.6%) | 2 (3.1%) | 10 (8.4%) | |
| Other | 7 (12.7%) | 7 (10.9%) | 14 (11.8%) | |
| What is the frequency (Heparin)? | | | | |
| Q6 | 2 (3.8%) | 0 (0%) | 2 (1.7%) | .501 |
| Q8 | 32 (60.4%) | 37 (59.7%) | 69 (60%) | |
| Q12 | 7 (13.2%) | 7 (11.3%) | 14 (12.2%) | |
| Other | 12 (22.6%) | 18 (29%) | 30 (26.1%) | |
| What is the dose you use (Enoxaparin)? | | | | |
| 30 mg | 8 (10%) | 7 (7.3%) | 15 (8.5%) | .153 |
| 40 mg | 42 (52.5%) | 63 (65.6%) | 105 (59.7%) | |
| 60 mg | 2 (2.5%) | 5 (5.2%) | 7 (4%) | |
| Based on patient weight/BMI | 26 (32.5%) | 17 (17.7%) | 43 (24.4%) | |
| Other | 2 (2.5%) | 4 (4.2%) | 6 (3.4%) | |
| What is the frequency (Enoxaparin)? | | | | |
| Q12 | 41 (51.3%) | 40 (41.2%) | 81 (45.8%) | .090 |
| Q24 | 28 (35%) | 49 (50.5%) | 77 (43.5%) | |
| Based on patient weight/BMI | 9 (11.3%) | 8 (8.3%) | 17 (9.6%) | |
| Other | 2 (2.5%) | 0 (0%) | 2 (1.1%) | |
| Do you use anti-Xa level to determine extended prophylaxis dosing? | | | | |
| No | 90 (93.8%) | 104 (95.4%) | 194 (94.6%) | .598 |
| Yes | 6 (6.3%) | 5 (4.6%) | 11 (5.4%) | |

VTE = venous thromboembolism; BMI = body mass index.

Data are expressed as n (%).

P-value is calculated using Chi-square or Fisher's exact test when appropriate.

Table 5

Complications of VTE prophylaxis during hospitalization

| Questions | Medical Directors | Membership | Total | P- value |
|---|-------------------|------------|-------------|----------|
| Do you modify the VTE prophylaxis protocol when concerned about bleeding risk? | | | | |
| No | 36 (31.9%) | 44 (35.5%) | 80 (33.8%) | .556 |
| Yes | 77 (68.1%) | 80 (64.5%) | 157 (66.2%) | |
| In your practice, have you seen any patients who received extended chemoprophylaxis and developed PE? | | | | |
| No | 92 (82.1%) | 99 (79.2%) | 191 (80.6%) | .557 |
| Yes | 20 (17.9%) | 26 (20.8%) | 46 (19.4%) | |
| Which postoperative complications would keep you from using extended chemoprophylaxis?* | | | | |
| Infection | 2 (1%) | 0 (0%) | 2 (.5%) | .222 |
| Return to operating room | 8 (4.2%) | 5 (2.6%) | 13 (3.4%) | .228 |
| Any bleeding | 23 (12%) | 26 (13.5%) | 49 (12.8%) | .955 |
| Bleeding requiring chemoprophylaxis cessation and observation | 53 (27.6%) | 48 (25%) | 101 (26.3%) | .141 |
| Bleeding requiring chemoprophylaxis cessation and blood transfusion | 48 (25%) | 48 (25%) | 96 (25%) | .464 |
| Bleeding requiring chemoprophylaxis cessation and reoperation | 41 (21.4%) | 46 (24%) | 87 (22.7%) | .968 |
| Other | 1 (.5%) | 0 (0%) | 1 (.3%) | .470 |
| None | 16 (8.3%) | 19 (9.9%) | 35 (9.1%) | .837 |
| In your practice, did your patients have any side effects from extended VTE chemoprophylaxis?* | | | | |
| Hematoma | 36 (22.5%) | 36 (21.2%) | 72 (21.8%) | .625 |
| Infection | 1 (.6%) | 0 (0%) | 1 (.3%) | .478 |
| Bleeding requiring chemoprophylaxis cessation and observation | 31 (19.4%) | 32 (18.8%) | 63 (19.1%) | .794 |
| Bleeding requiring chemoprophylaxis cessation and blood transfusion | 22 (13.8%) | 22 (13%) | 44 (13.3%) | .746 |
| Bleeding requiring chemoprophylaxis cessation and reoperation | 12 (7.5%) | 11 (6.5%) | 23 (7%) | .658 |
| Other | 5 (3.1%) | 2 (1.2%) | 7 (2.1%) | .263 |
| None | 53 (33.1%) | 67 (39.4%) | 120 (36.4%) | .246 |

VTE = venous thromboembolism; PE = pulmonary embolism.

Data are expressed as n (%).

P value is calculated using Chi-square or Fisher's exact test when appropriate.

* Multiple response questions.

Table 6

Criteria for extended VTE chemoprophylaxis postdischarge

| Questions | Medical directors | Membership | Total | P- value |
|--|-------------------|------------|-------------|----------|
| What are the criteria for extended chemoprophylaxis on discharge? [†] | | | | |
| Age | 11 (3.4%) | 9 (2.4%) | 20 (2.8%) | .541 |
| Gender | 8 (2.5%) | 5 (1.3%) | 13 (1.8%) | .331 |
| BMI > 40 | 1 (.3%) | 2 (.5%) | 3 (.4%) | 1.000 |
| BMI > 50 | 30 (9.2%) | 33 (8.7%) | 63 (8.9%) | .850 |
| BMI > 60 | 13 (4%) | 21 (5.5%) | 34 (4.8%) | .179 |
| Family or personal history of PE/DVT | 53 (16.2%) | 69 (18.1%) | 122 (17.2%) | .039 * |
| Immobility/paraplegia | 41 (12.5%) | 45 (11.8%) | 86 (12.2%) | .815 |
| Operative length | 9 (2.8%) | 12 (3.2%) | 21 (3%) | .576 |
| Based on risk calculator | 39 (11.9%) | 41 (10.8%) | 80 (11.3%) | .965 |
| Use of anticoagulants | 22 (6.7%) | 30 (7.9%) | 52 (7.3%) | .281 |
| Congestive heart failure | 5 (1.5%) | 8 (2.1%) | 13 (1.8%) | .448 |
| Length of stay | 3 (.9%) | 3 (.8%) | 6 (.9%) | 1.000 |
| COVID | 3 (.9%) | 4 (1.1%) | 7 (1%) | 1.000 |
| Pulmonary hypertension | 5 (1.5%) | 1 (.3%) | 6 (.9%) | .110 |
| Birth control pills/hormonal replacement | 8 (2.5%) | 9 (2.4%) | 17 (2.4%) | .896 |
| Inflammatory bowel disease | 1 (.3%) | 4 (1.1%) | 5 (.7%) | .369 |
| Venous stasis | 15 (4.6%) | 17 (4.5%) | 32 (4.5%) | .832 |
| Hypercoagulable state | 48 (14.7%) | 64 (16.8%) | 112 (15.8%) | .044 * |
| Other | 12 (3.7%) | 4 (1.1%) | 16 (2.3%) | .026 * |

VTE = venous thromboembolism; PE = pulmonary embolism; DVT = deep vein thrombosis.

Data are expressed as n (%).

P-value is calculated using Chi-square or Fisher's exact test when appropriate.

* The difference is significant at the .05 level.

[†] Multiple response questions.